Overview
The key safety topics selected for siponimod website are safety areas that are of interest to HCPs, such as infections including PML, CM and COVID-19 as well as reproductive toxicity that are related to the pharmacodynamic action of S1P modulators and effects of S1P modulators on the fetus
- The overall rate of infections was similar between the siponimod and placebo groups in controlled clinical trials (controlled pool)1; no increase in the overall incidence of infections was observed in patients treated long-term with siponimod (long-term pool)2
- To date, one case of PML has been reported for siponimod in clinical trial setting and two in postmarketing settings (1 attributed to siponimod and 1 to prior treatment with natalizumab)
- There were two cases of CM reported in the clinical trial setting. So far, there are no cases in the post-marketing setting.
- A total of 744 confirmed cases of COVID-19 were reported with siponimod treatment both in clinical trials and postmarketing setting; the majority (~80%) of the cases were non-serious
- In total, 37 cases of pregnancy were reported in the Novartis safety database, and data do not reveal any new safety risk of reproductive toxicity. No cases of congenital malformation and fetal or maternal complications related to pregnancy and delivery were reported in pregnant women exposed to siponimod
The safety data in the website will be updated annually in line with the PSUR. The sources of information used are the following:
1. Clinical trial data, which include controlled and long-term pools
- Controlled pool1: Double-blind, placebo-controlled core part of studies BOLD and EXPAND (siponimod 2 mg)
- Long-term pool2: Siponimod 2 mg or 10 mg (10 mg up to 24 months in BOLD extension) treatment period in the core (controlled and open-label) and/or extension phases of studies BOLD and EXPAND
2. Post-marketing experience, which is estimated based on the sales data in different countries where siponimod is approved3
BOLD4: Double-blind, randomized, adaptive, dose-ranging, placebo-controlled, parallel-group Phase 2 study
BOLD Extension5: Dose-blinded phase lasted up to 24 months followed by open-label siponimod 2 mg for approximately 3 years
EXPAND6: Double-blind, randomized, parallel-group, placebo-controlled, event-driven, exposure-driven, core-part, Phase 3 trial (up to 36 months), followed by an open-label extension part (up to 7 years/84 months)
|